| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 25mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Dehydroeburicoic acid monoacetate shows renoprotective activity in pig LLC-PK1 cells by inhibiting cisplatin-induced apoptosis. It modulates Bax, Bcl-2, caspase-3, and MAPK (JNK, ERK, p38) pathways. It demonstrates differential cytotoxicity across lung adenocarcinoma cell lines.
|
|---|---|
| ln Vitro |
In vitro, Dehydroeburicoic acid monoacetate shows differential cytotoxicity across four lung adenocarcinoma lines (A549, H1264, H1299, Calu-6) with IC50 values ranging from 63.6 to 108.0 μM. It shows renoprotective activity in pig LLC-PK1 cells by inhibiting cisplatin-induced apoptosis by 4.3% at concentrations ranging from 50 to 100 μM. It significantly reduces cisplatin-induced damage on cell viability, with inhibition levels of up to 80%.
|
| ln Vivo |
In vivo activity data for Dehydroeburicoic acid monoacetate are limited. Its renoprotective and cytotoxic activities in vitro suggest potential in vivo efficacy in models of kidney injury and cancer. Further in vivo studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Dehydroeburicoic acid monoacetate are conducted to evaluate its effects on apoptosis and MAPK pathways. Cisplatin-induced apoptosis is measured by annexin-V Alexa Fluor488/propidium iodide staining. Cell viability is assessed using the Ez-Cytox reagent assay. MAPK pathway proteins (JNK, ERK, p38) are analyzed by Western blotting.
|
| Cell Assay |
Cellular assays for Dehydroeburicoic acid monoacetate are performed using pig LLC-PK1 kidney cells and human lung adenocarcinoma cell lines (A549, H1264, H1299, Calu-6). Cells are treated with compound concentrations ranging from 50 to 100 µM. Apoptosis is evaluated by annexin-V/PI staining, and cell viability is assessed using the Ez-Cytox reagent assay.
|
| Animal Protocol |
In vivo animal studies for Dehydroeburicoic acid monoacetate would typically utilize rodent models of cisplatin-induced nephrotoxicity or tumor xenograft models of lung adenocarcinoma. The compound is administered orally or intraperitoneally. Endpoints include renal function markers, tumor growth, and histopathological evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Dehydroeburicoic acid monoacetate are not well characterized. The compound has a molecular weight of 510.75 and a molecular formula of C33H50O4. It is soluble in DMSO (1.25 mg/mL). As a lipophilic triterpenoid, it is expected to have good membrane permeability and oral absorption. Standard PK studies in rodents would be required.
|
| Toxicity/Toxicokinetics |
Toxicological data for Dehydroeburicoic acid monoacetate are limited. As a natural product-derived compound, it may have a moderate safety profile. No significant acute toxicity has been reported. The compound is designated for research use only.
|
| References | |
| Additional Infomation |
Reports indicate that dehydroepiandrosterone monoacetate has been found in plants of the Zizania genus, and relevant data are available for reference.
Dehydroeburicoic acid monoacetate is a lanostane-type triterpenoid from Poria cocos with renoprotective and cytotoxic activities. It shows differential cytotoxicity against lung adenocarcinoma cells (IC50: 63.6-108.0 μM) and inhibits cisplatin-induced apoptosis in LLC-PK1 cells. It has a molecular weight of 510.75 and formula C33H50O4. It is not clinically approved. |
| Molecular Formula |
C33H50O4
|
|---|---|
| Molecular Weight |
510.7477
|
| Exact Mass |
510.371
|
| CAS # |
77035-42-8
|
| PubChem CID |
15250827
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.136
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
37
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(C)C(=C)CC[C@H]([C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)OC(=O)C)C)C)C)C(=O)O
|
| InChi Key |
AYHCPTDPDUADTK-DLCVLMBDSA-N
|
| InChi Code |
InChI=1S/C33H50O4/c1-20(2)21(3)10-11-23(29(35)36)24-14-18-33(9)26-12-13-27-30(5,6)28(37-22(4)34)16-17-31(27,7)25(26)15-19-32(24,33)8/h12,15,20,23-24,27-28H,3,10-11,13-14,16-19H2,1-2,4-9H3,(H,35,36)/t23-,24-,27+,28+,31-,32-,33+/m1/s1
|
| Chemical Name |
(2R)-2-[(3S,5R,10S,13R,14R,17R)-3-acetyloxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9579 mL | 9.7895 mL | 19.5791 mL | |
| 5 mM | 0.3916 mL | 1.9579 mL | 3.9158 mL | |
| 10 mM | 0.1958 mL | 0.9790 mL | 1.9579 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
